Our biopharmaceutical business unit focuses on the research and development of both innovative biological and chemical entities.
It covers a wide spectrum of very diverse technologies, including complex small-molecule chemistries, medicinal chemistry, cell line development and recombinant protein production, protein purification and protein modification including (site-specific) conjugation, analytics, formulation and development of novel medicines. Read more about our strong scientific knowledge base.
Our principal technologies comprise antibody-drug conjugate (ADC) technology, including a unique linker-drug platform to generate novel ADC candidates, as well as monoclonal antibody (mAb) technology.
Antibody-drug conjugates are designed to combine the specificity of antibodies directed against tumor-associated targets with potent cytotoxicity. Upon internalization of the ADC, the antibody-bound cytotoxic payload is released intracellularly, leading to tumor cell death.
Monoclonal antibodies are glycoproteins that can very specifically bind to target antigens and are widely used against therapeutic targets in oncology and autoimmune treatments.